Approximately 75% of all disease-relevant human proteins, including those involved in
intracellular protein–protein interactions (PPIs), are undruggable with the current drug …

Our ever‐increasing understanding of biological systems is providing a range of exciting
novel biological targets, whose modulation may enable novel therapeutic options for many …

The aryl hydrocarbon receptor (AHR) is a ligand-dependent transcription factor regulating
adaptive and maladaptive responses toward exogenous and endogenous signals …

Protein–protein interactions (PPIs) have emerged as important and challenging targets in
chemical biology and medicinal chemistry. The main difficulty encountered in the discovery …

Targeting protein surfaces and protein–protein interactions (PPIs) with small molecules is a
frontier goal of chemical biology and provides attractive therapeutic opportunities in drug …

Objective—Although it is accepted that macrophage glycolysis is upregulated under hypoxic
conditions, it is not known whether this is linked to a similar increase in macrophage …

Macrocyclic peptides represent attractive scaffolds for targeting protein–protein interactions,
making methods for the diversification and functional selection of these molecules highly …

Highlights•SICLOPPS allows the rapid generation of cyclic peptide libraries in cells.•A
variety of cyclic peptide ring sizes may be generated with SICLOPPS.•SICLOPPS libraries …

The development of inhibitors that selectively block protein–protein interactions (PPIs) is
crucial for chemical biology, medicinal chemistry, and biomedical sciences. Herein, we …

Highlights•Cyclic peptides are an emerging class of drug modality for PPI
inhibition.•Rational design and library screening are established to generate lead …